IntroductionHomologous recombination (HR) is a major pathway of doublestrand break (DSB) repair in mammalian cells. 1 Faithful recombination is critical to avoid genetic and genomic aberrations, and involves a complex and orderly assembly of many checkpoints and repair factors. DSBs frequently occur as a result of exposure to irradiation and chemicals. In response to DSBs, activation of ataxia telangiectasia mutated (ATM) initiates a cascade of events, including phosphorylation of histone H2AX (referred to as ␥-H2AX) and downstream effectors such as structural chromosome maintenance 1 (SCM1) and checkpoint kinase 2 (Chk2). 2,3 Chk2 phosphorylates p53, disrupting its interaction with Mdm2 and stabilizing the p53 protein, 4 which pauses the cell cycle so that the cell can attempt to repair its damaged DNA. H2AX phosphorylation plays an important role in both DNA-damage-checkpoint activation and deactivation of the checkpoint signal to allow the cell cycle to resume. HR is very important during DNA replication in the S phase, when DSBs are generated during lagging strand synthesis or when unrepaired lesions cause replication-fork stalling. 5,6 Initiation of HR involves the recruitment of the MRE11/RAD50/NBS1 (MRN) complex to DNA-damaged sites that can be visualized by accumulation of ␥-H2AX as foci. 7 In contrast, DSBs created during the G1 or M phase are preferentially repaired by a nonconservative, nonhomologous-endjoining (NHEJ) pathway. The NHEJ pathway has been shown to be Ku80 and DNA-dependent protein kinase (DNA-PK) dependent. 8 The switch from HR to NHEJ has not been fully elucidated, but can in part be explained by the fact that MRE11-resection activity generates single-stranded DNA for which Ku80 has a poor affinity, allowing for the assembly of the MRN complex and HR repair. Therefore, regulation of DSB access to MRE11 or Ku80 is likely decisive in the fate and type of DNA repair.HTLV-1 is a human retrovirus associated with adult T-cell leukemia/lymphoma, an aggressive disease with a dismal prognosis. 9 Whereas the majority of HTLV-1-infected individuals remain asymptomatic, upwards of 5% of patients ultimately develop adult T-cell leukemia/lymphoma. The molecular mechanisms of HTLV-1 oncogenesis are poorly understood. HTLV-1 disrupts cell-cycle checkpoints, tumor suppressors, and Notch signaling and reactivates telomerase. [10][11][12][13] Unlike animal oncoretroviruses, HTLV-1 does not transduce a protooncogene and does not integrate at specific sites in the human genome, thereby excluding insertional mutagenesis. The end of the HTLV-1 proviral genome encodes for the regulatory proteins p12, p30, and the HTLV-1 bZIP factor (HBZ), which are involved in virus infectivity, immune escape, and establishment of latency. 14-17 HTLV-1 leukemic cells often present numerous genomic alterations, but the genesis and contribution of these chromosomal defects are presently unclear. The viral oncoprotein Tax plays an important role in the initiation of cellular transformation. In addition, several studies have shown...